The U.S. Food and Drug Administration has reaffirmed that CBD can’t be marketed as a dietary supplement. Two product applications from CBD companies, Charlotte’s Web and Irwin Naturals, were both denied in August. FDA rejected the two notifications as CBD is the active ingredient in the approved drug product Epidiolex and the agency would not let it be marketed as a dietary supplement.
FDA’s concerns focused on the scientific evidence submitted by the companies which the agency said did not provide an adequate basis to conclude that a dietary supplement would be safe. For these reasons, FDA ruled CBD products are excluded from the dietary supplement definition.
Although the FDA has claimed it wants to ensure consumer products containing CBD are safe, it has yet to act, which creates a major problem for the CBD industry. They are legally produced and used across the nation, but CBD products are currently not regulated at the federal level and state regulations vary, creating difficulties in transportation and sales.